HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment strategies to overcome end-of-dose failure with oral and transdermal opioids.

Abstract
Extended-release oral and transdermal opioids are increasingly being used for the management of chronic pain. Although the dosing intervals for these products were established through controlled clinical trials, expanded use of extended-release and transdermal dosage forms has resulted in awareness that a significant number of patients with chronic pain experience loss of baseline pain control prior to the next scheduled dose. End-of-dose failure (EDF) is the term used to describe this type of pain manifestation. By recognizing potential causes of EDF, strategies may be developed to overcome its occurrence to improve patients' pain control.
AuthorsLevi M Hall, Kathleen O'Lenic
JournalJournal of pharmacy practice (J Pharm Pract) Vol. 25 Issue 5 Pg. 503-9 (Oct 2012) ISSN: 1531-1937 [Electronic] United States
PMID23011962 (Publication Type: Journal Article, Review)
Chemical References
  • Analgesics, Opioid
  • Delayed-Action Preparations
Topics
  • Administration, Cutaneous
  • Administration, Oral
  • Analgesics, Opioid (administration & dosage, therapeutic use)
  • Breakthrough Pain (epidemiology, etiology, prevention & control)
  • Chronic Pain (drug therapy, physiopathology)
  • Delayed-Action Preparations (administration & dosage, therapeutic use)
  • Drug Therapy, Combination
  • Humans
  • Pain Management (methods)
  • Prevalence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: